The role of clinical trials in veterinary oncology

Veterinary Clinics of North America - Small Animal Practice

Volumn 44, Issue 5, 2014, Pages 977-987

  Burton, Jenna ^a   Khanna, Chand ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Clinical trials; Comparative oncology; Pathobiology; Veterinary

Indexed keywords

ADVERSE OUTCOME; ANIMAL CARE; ANIMAL HEALTH; ANIMAL WELFARE; CANCER RESEARCH; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; EVIDENCE BASED MEDICINE; GOOD CLINICAL PRACTICE; INFORMED CONSENT; MEDICAL ETHICS; ONCOLOGY; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROCESS DEVELOPMENT; REVIEW; RISK ASSESSMENT; STUDY DESIGN; VETERINARY MEDICINE; ANIMAL; CAT; CAT DISEASES; DOG; DOG DISEASES; NEOPLASMS; PET ANIMAL; TRENDS; VETERINARY;

ANTINEOPLASTIC AGENT;

ANIMALS; ANTINEOPLASTIC AGENTS; CAT DISEASES; CATS; CLINICAL TRIALS AS TOPIC; DOG DISEASES; DOGS; NEOPLASMS; PETS; VETERINARY MEDICINE;

EID: 84906738359     PISSN: 01955616     EISSN: 18781306     Source Type: Journal    
DOI: 10.1016/j.cvsm.2014.05.006     Document Type: Review

References (17)

1. Gordon I., Paoloni M., Mazcko C., et al. The Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med 2009, 6(10):e1000161.
2. Paoloni M., Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 2008, 8(2):147-156.
3. Paoloni M.C., Khanna C. Comparative oncology today. Vet Clin North Am Small Anim Pract 2007, 37(6):1023-1032.
4. Vail D.M. Cancer clinical trials: development and implementation. Vet Clin North Am Small Anim Pract 2007, 37(6):1033-1057. v.
5. Eisenhauer E.A., O'Dwyer P.J., Christian M., et al. Phase I clinical trial design in cancer drug development. JClin Oncol 2000, 18(3):684-692.
6. Kummar S., Gutierrez M., Doroshow J.H., et al. Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol 2006, 62(1):15-26.
7. Veterinary cooperative oncology group-common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol 2011, [Epub ahead of print].
8. Lee J.J., Feng L. Randomized phase II designs in cancer clinical trials: current status and future directions. JClin Oncol 2005, 23(19):4450-4457.
9. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10(1):1-10.
10. Nguyen S.M., Thamm D.H., Vail D.M., et al. Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet Comp Oncol 2013, [Epub ahead of print].
11. Vail D.M., Michels G.M., Khanna C., et al. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)-a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet Comp Oncol 2010, 8(1):28-37.
12. Ishak K.J., Proskorovsky I., Korytowsky B., et al. Methods for adjusting for bias due to crossover in oncology trials. Pharmacoeconomics 2014, 32(6):1-14.
13. Kummar S., Doroshow J.H., Tomaszewski J.E., et al. Phase 0 clinical trials: recommendations from the task force on methodology for the development of innovative cancer therapies. Eur J Cancer 2009, 45(5):741-746.
14. Takimoto C. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?. Cancer Chemother Pharmacol 2009, 63(4):703-709.
15. Jefford M., Moore R. Improvement of informed consent and the quality of consent documents. Lancet Oncol 2008, 9(5):485-493.
16. Zon R., Meropol N.J., Catalano R.B., et al. American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites. JClin Oncol 2008, 26(15):2562-2567.
17. McLemore M.R. The role of the data safety monitoring board: why was the Avastin phase III clinical trial stopped?. Clin J Oncol Nurs 2006, 10(2):153-154.